Manulife Singapore has joined Guardant Health, a precision oncology company, to offer eligible customers improved access to the Guardant360 liquid biopsy test. This will enable more Manulife customers with advanced solid tumour cancers to be matched with personalised treatments guided by liquid biopsy.
Through a simple blood draw, the Guardant360 test supports treatment decisions for Manulife customers with advanced solid tumour cancers. This provides comprehensive genomic profiling, delivering results within seven days of the laboratory receiving the sample. The test is particularly beneficial for customers who lack sufficient tumour tissue for in-depth testing.
“For a patient with an advanced solid tumour cancer, time to appropriate treatment is key. Our commitment remains to improve patient outcomes by helping oncologists match patients to the right targeted treatment quickly”
Simran Singh, CEO at Guardant Health AMEA
Liquid biopsies offer patients a more comfortable experience than tissue biopsies, as they are more convenient and less invasive, and they enable oncologists to identify targeted treatment strategies that are suitable for patients with advanced solid tumour cancers.
Specific eligibility criteria and further details to be announced at a later date.
“The collaboration with Guardant Health allows our financial consultants to provide more personalised advice, helping customers make more timely and informed decisions regarding their insurance options during critical moments. This is how we continue to raise the standard of care and protection for our customers.”
Dr Khoo Kah Siang, CEO of Manulife Singapore.
